Author details

Full Name

Jason T Huse

Affiliation

ORCID

Career Start Year

2000

Papers

179

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38060314	CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.	JCI Insight	2024
37603323	Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeutics.	Neuro Oncol	2024
37625115	Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.	Neuro Oncol	2024
37231247	Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.		2023
35868246	Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.	Neuro Oncol	2023
38039431	Exceptional Responses to Selpercatinib in Fusion-Driven Metastatic Pancreatic Cancer.		2023
37922934	A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.	Lancet Oncol	2023
37722850	Glial Cell Adhesion Molecule (GlialCAM) Determines Proliferative versus Invasive Cell States in Glioblastoma.		2023
36778278	Delineating genotypes and phenotypes of individual cells from long-read single cell transcriptomes.		2023
36711727	Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.	bioRxiv	2023
36510640	Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.	Neuro Oncol	2023
37131619	Interplay between and mutations governs innate immune responses in diffuse gliomas.		2023
37066184	Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.	bioRxiv	2023
37433798	High throughput single cell long-read sequencing analyses of same-cell genotypes and phenotypes in human tumors.		2023
37114244	Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience.	Neurooncol Adv	2023
37051329	Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle.	Neurooncol Adv	2023
36795646	Gibbs process distinguishes survival and reveals contact-inhibition genes in Glioblastoma multiforme.	PLoS One	2023
35021084	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.	Cell Reports	2022
36109124	Cellular Density in Adult Glioma, Estimated with MR Imaging Data and a Machine Learning Algorithm, Has Prognostic Power Approaching World Health Organization Histologic Grading in a Cohort of 1181 Patients.		2022
35906213	DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas.	Nat Commun	2022
35575067	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.	CNS Oncol	2022
36085890	Investigating Useful Features for Overall Survival Prediction in Patients with Low-Grade Glioma Using Histology Slides.	Annu Int Conf IEEE Eng Med Biol Soc	2022
35780432	A promising preclinical model for TERT promoter mutation in glioblastoma.	Neuro-Oncology	2022
35316217	Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.	JCI Insight	2022
34987156	Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.	Nat Commun	2022
35289001	Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.	Brain Pathology	2022
35175291	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.	Arch Pathol Lab Med	2022
35152274	The epigenetic dysfunction underlying malignant glioma pathogenesis.	Laboratory Investigation	2022
34691054	CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.	Front Immunol	2021
33625877	OncoTree: A Cancer Classification System for Precision Oncology.	JCO Clin Cancer Inform	2021
34244484	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.	Nat Commun	2021
33394124	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis.	Acta Neuropathol	2021
34496599	An international perspective on the management of glioblastoma.	Chinese Clinical Oncology	2021
34377987	Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience.	Neurooncol Adv	2021
34817712	The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.	Current Neurology and Neuroscience Reports	2021
31515460	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.	Clin Cancer Res	2020
31844891	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort.	Neuro Oncol	2020
32299815	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.	Clin Cancer Res	2020
32399739	Molecular markers and targeted therapy in pediatric low-grade glioma.	Journal of Neuro-Oncology	2020
31865407	<sup>18</sup>F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases.	Eur J Nucl Med Mol Imaging	2020
31755915	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.	Neuro Oncol	2020
32461334	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases.	Sci Transl Med	2020
32494639	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.	Sci Adv	2020
33040087	Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment.	Oncogene	2020
32587392	Robust detection of oncometabolic aberrations by H-C heteronuclear single quantum correlation in intact biological specimens.	Communications Biology	2020
33125861	YTHDF3 Induces the Translation of m<sup>6</sup>A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis.	Cancer Cell	2020
32669424	Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.	Science Translational Medicine	2020
32721947	Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration.	JCI Insight	2020
30963577	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.	Int J Cancer	2020
31097032	Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype.	Acta Neuropathol Commun	2019